<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Bioxcel Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc</link>
<description>Latest news and press releases for Bioxcel Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/bioxcel-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835505078dffbe2df0e7259.webp</url>
<title>Bioxcel Therapeutics Inc</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc</link>
</image>
<item>
<title>BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-virtual-event-to-discuss-commercial-launch-plan-based-on-market-opportunity-assessment-for-igalmir-in-the-at-home-setting</guid>
<pubDate>Fri, 17 Apr 2026 11:00:00 GMT</pubDate>
<description>Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn., April 17, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it will host a virtual event on Thursday, April 23, from 2:00 to 3:00 p.m. ET. The event will center on the Company</description>
</item>
<item>
<title>BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-us-department-of-war-funded-study-of-bxcl501-sublingual-dexmedetomidine-for-treatment-of-acute-stress-reactions</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-enrollment-of-first-patients-in-us-department-of-war-funded-study-of-bxcl501-sublingual-dexmedetomidine-for-treatment-of-acute-stress-reactions</guid>
<pubDate>Wed, 08 Apr 2026 04:00:00 GMT</pubDate>
<description>DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially</description>
</item>
<item>
<title>BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-food-and-drug-administration-acceptance-of-supplemental-new-drug-application-for-use-of-igalmir-in-the-at-home-setting</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-food-and-drug-administration-acceptance-of-supplemental-new-drug-application-for-use-of-igalmir-in-the-at-home-setting</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>PDUFA target action date of November 14, 2026 Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar</description>
</item>
<item>
<title>BioXcel Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results as Company Prepares for Potential IGALMI® Approval in Outpatient Setting</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-as-company-prepares-for-potential-igalmir-approval-in-outpatient-setting</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-as-company-prepares-for-potential-igalmir-approval-in-outpatient-setting</guid>
<pubDate>Fri, 27 Mar 2026 04:00:00 GMT</pubDate>
<description>sNDA submitted seeking approval of IGALMI® in the at-home (outpatient) setting for the treatment of acute agitation associated with bipolar disorders or</description>
</item>
<item>
<title>BioXcel Therapeutics Announces Closing of $8.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-closing-of-dollar80-million-registered-direct-offering-30</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-closing-of-dollar80-million-registered-direct-offering-30</guid>
<pubDate>Wed, 11 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., March 11, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on</description>
</item>
<item>
<title>BioXcel Therapeutics Announces Approximately $8.0 Million Registered Direct Offering</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-approximately-dollar80-million-registered-direct-offering</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-approximately-dollar80-million-registered-direct-offering</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company built on</description>
</item>
<item>
<title>BioXcel Therapeutics Announces Positive Phase 2 Topline Results from Columbia University-Led Study of BXCL501 for Treatment of Opioid Withdrawal</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-positive-phase-2-topline-results-from-columbia-university-led-study-of-bxcl501-for-treatment-of-opioid-withdrawal-6</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-positive-phase-2-topline-results-from-columbia-university-led-study-of-bxcl501-for-treatment-of-opioid-withdrawal-6</guid>
<pubDate>Thu, 05 Mar 2026 05:00:00 GMT</pubDate>
<description>BXCL501 demonstrated clinical benefits and favorable tolerability profile for treatment of opioid withdrawal symptoms Results from this NIDA-funded study</description>
</item>
<item>
<title>BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer’s Dementia</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-to-host-virtual-roundtable-featuring-leading-medical-experts-addressing-latest-developments-in-treatment-of-acute-agitation-in-alzheimers-dementia</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-to-host-virtual-roundtable-featuring-leading-medical-experts-addressing-latest-developments-in-treatment-of-acute-agitation-in-alzheimers-dementia</guid>
<pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
<description>Discussion will focus on the high unmet need and the lack of FDA-approved treatment options associated with acute agitation episodes in Alzheimer’s dementia</description>
</item>
<item>
<title>BioXcel Therapeutics Completes Market Opportunity Assessment and Advances Commercialization Plans for IGALMI® in the At-Home Setting</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-completes-market-opportunity-120000333</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-completes-market-opportunity-120000333</guid>
<pubDate>Thu, 12 Feb 2026 12:00:00 GMT</pubDate>
<description>Third party commercial assessment shows larger than expected potential total addressable market for IGALMI® in the at-home setting Strong prescriber interest, patient demand, and positive payer feedback on formulary coverage NEW HAVEN, Conn., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced the completion of an updated market opportu</description>
</item>
<item>
<title>Rigel Appoints Michael P. Miller to the Board of Directors</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/rigel-appoints-michael-p-miller-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/rigel-appoints-michael-p-miller-to-the-board-of-directors</guid>
<pubDate>Tue, 03 Feb 2026 13:05:00 GMT</pubDate>
<description>Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller has more than four decades of experience in commercial and leadership roles in the biotechnology and pharmaceutical industries.</description>
</item>
<item>
<title>BioXcel Therapeutics Submits Supplemental New Drug Application to U.S. Food and Drug Administration for IGALMI® Label Expansion in the At-Home Setting</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-submits-supplemental-drug-120000427</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-submits-supplemental-drug-120000427</guid>
<pubDate>Tue, 20 Jan 2026 12:00:00 GMT</pubDate>
<description>sNDA submission supports the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting with IGALMI® Submission timeline supports potential approval of IGALMI® label expansion as early as year-end 2026 NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced it submit</description>
</item>
<item>
<title>BioXcel Therapeutics Expands Leadership Team to Prepare for Launch of IGALMI® in the At-Home Setting</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-expands-leadership-team-120000630</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-expands-leadership-team-120000630</guid>
<pubDate>Mon, 12 Jan 2026 12:00:00 GMT</pubDate>
<description>Mark Pavao to Join BioXcel Therapeutics as Interim Chief Commercial Officer Mr. Pavao Brings Deep Experience in Neuroscience Sales and Marketing to Support Potential Launch of IGALMI® in At-Home Setting as Early as Year-End 2026 BioXcel Therapeutics on Track to Submit a sNDA for IGALMI® this Month NEW HAVEN, Conn., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in</description>
</item>
<item>
<title>BioXcel Therapeutics Planning to Submit sNDA This Month Seeking FDA Approval for At-Home Use of IGALMI®</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-planning-submit-snda-120000430</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-planning-submit-snda-120000430</guid>
<pubDate>Wed, 07 Jan 2026 12:00:00 GMT</pubDate>
<description>Company remains focused on potential approval and launch of IGALMI® for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home settingNEW HAVEN, Conn., Jan. 07, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial intelligence (“AI”) to develop transformative medicines in neuroscience, today announced that it plans to submit a supplemental New Drug Application (sNDA) this month seeking the</description>
</item>
<item>
<title>Award-Winning Journalist Anjalee Khemlani to Host Virtual Roundtable with Leading Medical Experts to Discuss Latest Developments in Treating Acute Agitation Related to Neuropsychiatric Conditions</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/award-winning-journalist-anjalee-khemlani-120000087</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/award-winning-journalist-anjalee-khemlani-120000087</guid>
<pubDate>Wed, 03 Dec 2025 12:00:00 GMT</pubDate>
<description>Event Sponsored by BioXcel Therapeutics Set for 10 a.m. EST on Monday, Dec. 8 Topics Covered by Drs. Leslie Citrome, Marc Milano, and Leon Ravin to Include Opportunities and Advantages of Self-Administered Treatments at Home NEW HAVEN, Conn., Dec. 03, 2025 (GLOBE NEWSWIRE) -- As millions of patients and caregivers continue to struggle with acute agitation episodes associated with bipolar disorder and schizophrenia, a timely and highly anticipated virtual roundtable will bring together leading me</description>
</item>
<item>
<title>BioXcel Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on Late-Stage Clinical Programs for Agitation in Bipolar, Schizophrenia, and Alzheimer’s Disease</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-reports-third-quarter-120000279</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-reports-third-quarter-120000279</guid>
<pubDate>Wed, 12 Nov 2025 12:00:00 GMT</pubDate>
<description>sNDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the SERENITY At-Home trialNEW HAVEN, Conn., Nov. 12, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today reported financial results for the third quarter of 2025 and provided an update on its late-stage agitation clinical development programs. As</description>
</item>
<item>
<title>BioXcel Therapeutics Announces Positive Results from Correlation Study Supporting SERENITY At-Home Exploratory Efficacy Outcomes</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-positive-results-110000899</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-announces-positive-results-110000899</guid>
<pubDate>Tue, 14 Oct 2025 11:00:00 GMT</pubDate>
<description>Completes clinical trials required by FDA for sNDA submission planned for the first quarter of 2026NEW HAVEN, Conn., Oct. 14, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced positive results from the correlation study related to exploratory efficacy outcomes from the SERENITY At-Home trial. The results, along with the data from the SERENITY At-Hom</description>
</item>
<item>
<title>BioXcel Therapeutics to Ring Nasdaq Closing Bell on October 14 to Celebrate a Transformative Milestone in Neuroscience Innovation</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-ring-nasdaq-closing-110000532</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-ring-nasdaq-closing-110000532</guid>
<pubDate>Mon, 13 Oct 2025 11:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Oct. 13, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company pioneering the use of artificial intelligence to develop transformative medicines in neuroscience, announced today that CEO Vimal Mehta, Ph.D., and members of the BioXcel team will ring the Nasdaq Stock Market Closing Bell on Tuesday, October 14, 2025. This honor marks a pivotal moment for the company — celebrating BioXcel’s breakthrough progress in addressing one of the mos</description>
</item>
<item>
<title>BioXcel Therapeutics Regains Compliance with Nasdaq Market Value of Listed Securities Requirements</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-regains-compliance-nasdaq-110000658</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-regains-compliance-nasdaq-110000658</guid>
<pubDate>Thu, 18 Sep 2025 11:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Sept. 18, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that it has received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with the market value of listed securities (“MVLS”) requirement under Nasdaq Listing Rule 5550(b)(2) (the “MVLS</description>
</item>
<item>
<title>BioXcel Therapeutics Reports Positive Topline Exploratory Efficacy Data from SERENITY At-Home Pivotal Phase 3 Safety Trial for Agitation Associated with Bipolar Disorders or Schizophrenia</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-reports-positive-topline-103000107</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-reports-positive-topline-103000107</guid>
<pubDate>Wed, 10 Sep 2025 10:30:00 GMT</pubDate>
<description>BXCL501 demonstrated a significant mean reduction in mCGI-S score from baseline compared to placebo at 2 hours across 2,433 treated episodes (p<.05) Complete resolution of agitation was significantly higher with BXCL501 compared to placebo across agitation episode severity (p<.0001) BXCL501 showed a similar reduction in agitation symptoms over both the duration of the trial and number of treated episodes, demonstrating continued effects and consistent benefit with repeat dosing of BXCL501 Based</description>
</item>
<item>
<title>BioXcel Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-present-h-c-110000966</link>
<guid isPermaLink="true">https://6ix.com/company/bioxcel-therapeutics-inc/news/bioxcel-therapeutics-present-h-c-110000966</guid>
<pubDate>Thu, 04 Sep 2025 11:00:00 GMT</pubDate>
<description>NEW HAVEN, Conn., Sept. 04, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience, today announced that Vimal Mehta, Ph.D., CEO of BioXcel Therapeutics, will present a company overview at the H.C. Wainwright 27th Annual Global Investment Conference to be held September 8 - 10, 2025. Date: Monday, September 8, 2025Time: 4:30 p.m. Eastern TimeWebcast Link: HERE The live a</description>
</item>
</channel>
</rss>